Latest Content
The challenges of neoadjuvant trials, what we learnt from NAXIVA
NAXIVA is the first clinical trial to evaluate neoadjuvant downstaging of patients with the unique biological phenomenon of venous tumour thrombus in kidney cancer. But what did we learn beyond the endpoints?
Cancer Diagnosis- Delivering Difficult News to Patients and Families
"Each day comes bearing its own gifts. Untie the ribbons." — Ruth Ann Schabacker.
Reflections on being an Oncologist
"I am honored to take care of persons living with cancer, it’s a privilege with sober responsibilities"
Dr. Omar, Clinical Oncologist
Behind the Paper
The real stories behind the latest research papers, from conception to publication, the highs and the lows.
The challenges of neoadjuvant trials, what we learnt from NAXIVA
NAXIVA is the first clinical trial to evaluate neoadjuvant downstaging of patients with the unique biological phenomenon of venous tumour thrombus in kidney cancer. But what did we learn beyond the endpoints?
Springer Nature launches Research Digests with Scientific American
Springer Nature has launched a new service where research authors can purchase a promotional article on Scientific American to explain their science to a public audience
Africa and Cancer
Facilitating collaborative cancer research programs and research capacities in Africa
Cancer Diagnosis- Delivering Difficult News to Patients and Families
"Each day comes bearing its own gifts. Untie the ribbons." — Ruth Ann Schabacker.
Reflections on being an Oncologist
"I am honored to take care of persons living with cancer, it’s a privilege with sober responsibilities"
Dr. Omar, Clinical Oncologist
Black in Cancer
Strengthening networks and highlighting Black excellence in cancer research and medicine.
Opportunities to join the Nature Communications editorial team
We are seeking two cancer research experts to join our cancer team; one role is for a permanent team member, the second role is for a locum - or a temporary position.
Sponsored by
